Olson David E
Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, California 95616, United States.
Department of Biochemistry & Molecular Medicine, School of Medicine, University of California, Davis, 2700 Stockton Blvd, Suite 2102, Sacramento, California 95817, United States.
ACS Pharmacol Transl Sci. 2020 Dec 10;4(2):563-567. doi: 10.1021/acsptsci.0c00192. eCollection 2021 Apr 9.
Psychedelics represent one of the most promising classes of experimental medicines for the treatment of neuropsychiatric disorders due to their ability to promote neural plasticity and produce both rapid and sustained therapeutic effects following a single administration. Conventional wisdom holds that peak mystical experiences induced by psychedelics are a critical component of their therapeutic mechanisms of action, though evidence supporting that claim is largely correlational. Here, I present data suggesting that the subjective effects induced by psychedelics may not be necessary to produce long-lasting changes in mood and behavior. Understanding the role of subjective effects in the therapeutic mechanisms of psychedelics will have important implications for both basic neuroscience and for increasing patient access to the next generation of medicines developed as a result of psychedelic research.
由于具有促进神经可塑性以及单次给药后能产生快速且持续治疗效果的能力，迷幻药是治疗神经精神疾病最有前景的一类实验性药物之一。传统观点认为，迷幻药引发的巅峰神秘体验是其治疗作用机制的关键组成部分，尽管支持这一说法的证据大多是相关性的。在此，我展示的数据表明，迷幻药诱发的主观效应可能并非产生情绪和行为持久变化所必需的。了解主观效应在迷幻药治疗机制中的作用，将对基础神经科学以及增加患者获得因迷幻药研究而开发的新一代药物的机会都具有重要意义。
